2023 Volume 60 Issue 1 Pages 51-56
Four patients with relapsed/refractory medulloblastoma were treated with bevacizumab/irinotecan/temozolomide triple therapy, together with an intrathecal methotrexate injection. Three patients achieved sustained progression-free survival and improved quality of life. One patient managed to live for up to 54 months after relapsing. This treatment regimen was applied as a bridging therapy in an infant with disease refractory to conventional treatment, thus allowing craniospinal irradiation at the age of three and resulting in long-term remission. No severe adverse effects necessitating the termination of treatment were noted, although the development of severe myelosuppression caused by prolonged repeated administration should be considered. In terms of efficacy and safety compared with the current therapy, bevacizumab/irinotecan/temozolomide triple therapy may be an alternative for treating relapsed/refractory medulloblastoma.
